Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 4 May 2026. This revision reflects a combination of deteriorating technical indicators, expensive valuation metrics, and flat financial trends, despite the company’s strong management efficiency and long-term market-beating returns.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish to a mildly bearish stance. Despite a 2.53% gain on 5 May 2026, the company’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, prompting a downgrade in its Mojo Grade from Hold to Sell.

Gujarat Themis Biosyn Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality. The upgrade, effective from 29 April 2026, follows a period of mixed performance but notable resilience in a challenging pharmaceuticals sector environment.

Gujarat Themis Biosyn Ltd has exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This transition is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a robust day gain of 3.97%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, warranting a nuanced analysis for investors.

The Sensex declined by 1.07% on 24 Apr 2026, while Gujarat Themis Biosyn Ltd surged 9.74%, outperforming its Pharmaceuticals & Biotechnology sector by 10.65 percentage points. This sharp single-session gain stands out as a stock-specific event amid a broadly weak market environment.

Gujarat Themis Biosyn Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across multiple timeframes. Despite a recent upgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical indicators suggest a cautious outlook for investors navigating this evolving landscape.

Gujarat Themis Biosyn Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

The Sensex climbed 3.97% on 8 Apr 2026, yet Gujarat Themis Biosyn Ltd outpaced the market with a 7.34% gain, touching an intraday high of Rs 283. This 6.45-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector signals a notable stock-specific momentum shift.

Gujarat Themis Biosyn Ltd witnessed a robust start to trading on 6 April 2026, opening with a notable gap up of 5.37%, reflecting positive market sentiment despite a recent downgrade in its Mojo Grade to 'Sell'. The stock outperformed its sector and broader indices, continuing a three-day upward trend that has delivered nearly 15% returns in that period.

The Sensex advanced 2.7% on 1 Apr 2026, yet Gujarat Themis Biosyn Ltd outperformed sharply with an 8.07% gain, marking a notable single-session rebound. This 3.14-percentage-point outperformance against its Pharmaceuticals & Biotechnology sector peers highlights a stock-specific event rather than a broad market lift.

Gujarat Themis Biosyn Ltd experienced a significant intraday decline on 30 Mar 2026, touching a day low of Rs 230.05, down 8.55% from the previous close. The stock underperformed its sector and broader market indices, reflecting immediate selling pressure amid a broadly bearish market environment.

Gujarat Themis Biosyn Ltd is rated Sell by MarketsMOJO. This rating was last updated on 21 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 29 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Shares of Gujarat Themis Biosyn Ltd declined sharply on 23 Mar 2026, hitting an intraday low of Rs 254.95, reflecting a significant price pressure that outpaced sector and benchmark indices amid a broadly bearish market environment.

Gujarat Themis Biosyn Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with an up-to-date perspective on the company's fundamentals, valuation, financial trends, and technical outlook.